Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 2/20 | 0.51 |
| ▸ | BCHE | P06276 | 3/20 | 0.50 |
| ▸ | ACHE | P22303 | 3/20 | 0.50 |
| ▸ | BACE1 | P56817 | 3/20 | 0.50 |
| ▸ | RORC | P51449 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21105435 | 1.00 | TACR1 (0.51) | TACR1BCHEACHEBACE1RORC | |
| SCHEMBL16226782 | 0.90 | SIGMAR1 (0.55) | DRD4SIGMAR1LMNA | |
| SCHEMBL82746 | 0.86 | RORC (0.52) | BCHEACHEBACE1RORCSIGMAR1 | |
| SCHEMBL83046 | 0.82 | DRD2 (0.47) | TACR1BCHEACHEBACE1DRD4 | |
| SCHEMBL83711 | 0.82 | HRH3 (0.50) | SIGMAR1 | |
| SCHEMBL16422537 | 0.77 | ACHE (0.49) | TACR1BCHEACHEBACE1DRD4 | |
| SCHEMBL21105516 | 0.77 | RORC (0.46) | BCHEACHEBACE1RORCSIGMAR1 | |
| SCHEMBL16644677 | 0.77 | RORC (0.46) | BCHEACHEBACE1RORCSIGMAR1 | |
| SCHEMBL5557480 | 0.77 | DRD4 (0.60) | DRD4SIGMAR1HTTLMNA | |
| SCHEMBL5557482 | 0.77 | DRD4 (0.60) | DRD4SIGMAR1HTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3057963-B1 | PIPERAZINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM INT (DE) | 2019-06-19 | — | — | EP | disclosed |
| US-9233953-B2 | Derivatives of 4-(piperazinylcarbonyl)thiane-1, 1-dione which inhibit GlyT1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-01-12 | — | — | US | disclosed |
| US-9233953-B2 | Derivatives of 4-(piperazinylcarbonyl)thiane-1, 1-dione which inhibit GlyT1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-01-12 | — | — | US | disclosed |
| WO-2015055698-A1 | PIPERAZINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-23 | — | — | WO | disclosed |
| US-20150105397-A1 | Piperazine derivatives and the use thereof as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-16 | — | — | US | disclosed |
| US-20150105397-A1 | Piperazine derivatives and the use thereof as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105397-A1 | Piperazine derivatives and the use thereof as medicament | SLC6A7, SLC7A11, SLC7A1 | TACR1 366/4885BCHE 2844/4885ACHE 3685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.